Oppenheimer Reconfirms $51 Target On UroGen Pharma Ltd (URGN), Reconfirms Outperform Rating; Anchor Capital Advisors Lifted Veritiv (VRTV) Stake

November 15, 2017 - By Michael Collier

Anchor Capital Advisors Llc increased Veritiv Corp (VRTV) stake by 51.83% reported in 2017Q2 SEC filing. Anchor Capital Advisors Llc acquired 19,591 shares as Veritiv Corp (VRTV)’s stock declined 19.42%. The Anchor Capital Advisors Llc holds 57,388 shares with $2.58 million value, up from 37,797 last quarter. Veritiv Corp now has $372.88M valuation. The stock rose 0.21% or $0.05 reaching $23.75 per share. About shares traded. Veritiv Corp (NYSE:VRTV) has risen 28.48% since November 15, 2016 and is uptrending. It has outperformed by 11.78% the S&P500.

Among 4 analysts covering UroGen Pharma Ltd. – Ordinary Shares (URGN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. UroGen Pharma Ltd. – Ordinary Shares has $37 highest and $2500 lowest target. $31.33’s average target is -21.71% below currents $40.02 stock price. UroGen Pharma Ltd. – Ordinary Shares had 8 analyst reports since May 30, 2017 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $37 target in Monday, October 9 report. As per Tuesday, May 30, the company rating was initiated by Raymond James. Jefferies initiated Urogen Pharma Ltd (NASDAQ:URGN) rating on Tuesday, May 30. Jefferies has “Buy” rating and $2700 target. On Friday, July 14 the stock rating was maintained by Oppenheimer with “Buy”. The rating was maintained by Cowen & Co with “Buy” on Wednesday, July 19. The stock has “Buy” rating by Oppenheimer on Monday, August 14. Oppenheimer initiated the stock with “Buy” rating in Tuesday, May 30 report.

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel clinical-stage biopharmaceutical company. The company has market cap of $520.64 million. It is engaged in developing therapies designed to care for urological pathologies. It currently has negative earnings. The Company’s lead product candidates include MitoGel and VesiGel.

About 12 shares traded. Urogen Pharma Ltd (URGN) has 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Anchor Capital Advisors Llc decreased At&T Inc (NYSE:T) stake by 16,263 shares to 785,184 valued at $29.63 million in 2017Q2. It also reduced Intel Corp (NASDAQ:INTC) stake by 70,201 shares and now owns 66,209 shares. Community Bk Sys Inc (NYSE:CBU) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By : XYZScripts.com